Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion - A Review

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. Gel-Based Proteomics of Clinical Samples Identifies Potential Serological Biomarkers for Early Detection of Colorectal Cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Methods and guidelines for measurement of glucagon in plasma

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Xeno-Free Propagation of Spermatogonial Stem Cells from Infant Boys

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Matrix Metalloproteinase-3 is Key Effector of TNF-α-Induced Collagen Degradation in Skin

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. GIP's effect on bone metabolism is reduced by the selective GIP receptor antagonist GIP(3-30)NH2

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Gluco-metabolic effects of pharmacotherapy-induced modulation of bile acid physiology

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Effect of the incretin hormones on the endocrine pancreas in end-stage renal disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. N-acyl taurines are endogenous lipid messengers that improve glucose homeostasis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

The gut-derived incretin hormones glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are secreted after meal ingestion and work in concert to promote postprandial insulin secretion. Furthermore, GLP-1 inhibits glucagon secretion when plasma glucose concentrations are above normal fasting concentrations while GIP acts glucagonotropically at low glucose levels. A dual incretin receptor agonist designed to co-activate GLP-1 and GIP receptors was recently shown to elicit robust improvements of glycemic control (mean haemoglobin A1c reduction of 1.94%) and massive body weight loss (mean weight loss of 11.3 kg) after 26 weeks of treatment with the highest dose (15 mg once weekly) in a clinical trial including overweight/obese patients with type 2 diabetes. Here, we describe the mechanisms by which the two incretins modulate alpha cell secretion of glucagon, review the effects of co-administration of GLP-1 and GIP on glucagon secretion, and discuss the potential role of glucagon in the therapeutic effects observed with novel unimolecular dual GLP-1/GIP receptor agonists. For clinicians and researchers, this manuscript offers an understanding of incretin physiology and pharmacology, and provides mechanistic insight into future antidiabetic and obesity treatments.

OriginalsprogEngelsk
Artikelnummer4092
TidsskriftInternational Journal of Molecular Sciences
Vol/bind20
Udgave nummer17
ISSN1661-6596
DOI
StatusUdgivet - 22 aug. 2019

ID: 57856582